Cargando…

Predicting treatment response of patients with extranodal natural killer/T‐cell lymphoma based on levels of PD‐L1 mRNA and soluble PD‐L1

Appropriate biomarkers may help predict patient response to treatment for extranodal natural killer/T‐cell lymphoma (ENKTL), a subtype of non‐Hodgkin's lymphoma in China. Programmed cell death receptor 1 (PD‐1) and its ligand (PD‐L1) have been investigated in various tumors. However, few studie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Feng, Yu, Jing, Caixia, Yu, Xinmei, Cao, Xia, Xu, Caigang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2020
Materias:	Original Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7689790/ https://www.ncbi.nlm.nih.gov/pubmed/32515093 http://dx.doi.org/10.1002/hon.2758

Ejemplares similares

VISTA and PD-L1 synergistically predict poor prognosis in patients with extranodal natural killer/T-cell lymphoma
por: He, Hai-Xia, et al.
Publicado: (2021)

The Role of PD-L1 Expression in Prediction and Stratification of Recurrent or Refractory Extranodal Natural Killer/T-Cell Lymphoma
por: Gao, Li-Min, et al.
Publicado: (2022)

GM-CSF mediates immune evasion via upregulation of PD-L1 expression in extranodal natural killer/T cell lymphoma
por: Rong, Qi-xiang, et al.
Publicado: (2021)

Coexpression of PD-L1/PD-1 with CXCR3/CD36 and IL-19 Increase in Extranodal Lymphoma
por: Saber, Manal Mohamed
Publicado: (2023)

The expression and clinical significance of programmed cell death receptor 1 and its ligand in tumor tissues of patients with extranodal nasal NK/T cell lymphoma
por: Feng, Yu, et al.
Publicado: (2022)

Exosomal and Soluble Programed Death-Ligand 1 (PD-L1) Predicts Responses to Pembrolizumab in Patients with Extranodal NK/T-Cell Lymphoma
por: Kim, Seok Jin, et al.
Publicado: (2022)

PD-L1-expressing extranodal diffuse large B-cell lymphoma, NOS with and without PD-L1 3’-UTR structural variations
por: Takahara, Taishi, et al.
Publicado: (2022)

Expression of PD-L1 on Monocytes Is a Novel Predictor of Prognosis in Natural Killer/T-Cell Lymphoma
por: Zhang, Xue-wen, et al.
Publicado: (2020)

Burgeoning Exploration of the Role of Natural Killer Cells in Anti-PD-1/PD-L1 Therapy
por: Bai, Rilan, et al.
Publicado: (2022)

Biological Characteristics and Clinical Significance of Soluble PD-1/PD-L1 and Exosomal PD-L1 in Cancer
por: Niu, Mengke, et al.
Publicado: (2022)

Soluble PD-1 and PD-L1: predictive and prognostic significance in cancer
por: Zhu, Xinxin, et al.
Publicado: (2017)

Currently Used Laboratory Methodologies for Assays Detecting PD-1, PD-L1, PD-L2 and Soluble PD-L1 in Patients with Metastatic Breast Cancer
por: Jeong, Seri, et al.
Publicado: (2021)

Robust Preanalytical Performance of Soluble PD-1, PD-L1 and PD-L2 Assessed by Sensitive ELISAs in Blood
por: Krueger, Kimberly, et al.
Publicado: (2022)

PD-1, PD-L1 and PD-L2 Gene Expression on T-Cells and Natural Killer Cells Declines in Conjunction with a Reduction in PD-1 Protein during the Intensive Phase of Tuberculosis Treatment
por: Hassan, Syeda S., et al.
Publicado: (2015)

Effect of Primary Systemic Therapy on PD-1, PD-L1, and PD-L2 mRNA Expression in Advanced Breast Cancer
por: Karsono, Ramadhan, et al.
Publicado: (2021)

High Quality Performance of Novel Immunoassays for the Sensitive Quantification of Soluble PD-1, PD-L1 and PD-L2 in Blood
por: Krueger, Kimberly, et al.
Publicado: (2022)

Extranodal Natural-Killer/T-Cell Lymphoma, Nasal Type
por: Gill, Harinder, et al.
Publicado: (2010)

Extranodal natural killer/T-cell lymphoma of the tenosynovium of the hand
por: Lim, Yoo Li, et al.
Publicado: (2015)

Extranodal Natural Killer/T-Cell Lymphoma: An Incidental Finding
por: Althoff, Ashley, et al.
Publicado: (2017)

Interferon-γ induced PD-L1 expression and soluble PD-L1 production in gastric cancer
por: Imai, Yushi, et al.
Publicado: (2020)

Clinical PD-1/PD-L1 Blockades in Combination Therapies for Lymphomas
por: Katsuya, Hiroo, et al.
Publicado: (2023)

A Case of Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type with Dermatomyositis
por: Gong, Yu, et al.
Publicado: (2021)

Skin lesion of extranodal natural killer/T‐cell lymphoma nasal type
por: Okumura, Koichiro, et al.
Publicado: (2021)

PD-L1 Status in Refractory Lymphomas
por: Vranic, Semir, et al.
Publicado: (2016)

Therapeutic plasma exchange clears circulating soluble PD-L1 and PD-L1-positive extracellular vesicles
por: Orme, Jacob J, et al.
Publicado: (2020)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma
por: Bi, Xi-wen, et al.
Publicado: (2016)

Overexpression of PD‐L1 causes germ cells to slough from mouse seminiferous tubules via the PD‐L1/PD‐L1 interaction
por: Fang, Lian, et al.
Publicado: (2022)

Successful targeting of PD-1/PD-L1 with chimeric antigen receptor-natural killer cells and nivolumab in a humanized mouse cancer model
por: Liu, Wai Nam, et al.
Publicado: (2022)

Extranodal natural killer/T-cell lymphoma presenting as orbital cellulitis
por: Zuhaimy, Hanis, et al.
Publicado: (2017)

P1240: ANTI-PD-1-ANTIBODY (TISLELIZUMAB) COMBINED WITH DEACETYLASE INHIBITOR (CHIDAMIDE), LENALIDOMIDE AND ETOPOSIDE FOR THE TREATMENT OF REFRACTORY/RELAPSED EXTRANODAL NATURAL KILLER/T CELL LYMPHOMA, NASAL
por: Zhang, L., et al.
Publicado: (2022)

Soluble PD-1 but Not PD-L1 Levels Predict Poor Outcome in Patients with High-Risk Diffuse Large B-Cell Lymphoma
por: Vajavaara, Heli, et al.
Publicado: (2021)

Mevalonate improves anti-PD-1/PD-L1 efficacy by stabilizing CD274 mRNA
por: Zhang, Wenxin, et al.
Publicado: (2023)

Prognostic significance of peripheral monocyte count in patients with extranodal natural killer/T-cell lymphoma
por: Huang, Jia-Jia, et al.
Publicado: (2013)

The significance of PD-1/PD-L1 imbalance in ulcerative colitis
por: Shi, Wei, et al.
Publicado: (2023)

Expression of PD-1/PD-L1 in peripheral blood and tumor tissues of patients with classical Hodgkin’s lymphoma
por: Feng, Xia, et al.
Publicado: (2023)

Progress of research on PD-1/PD-L1 in leukemia
por: Cao, Huizhen, et al.
Publicado: (2023)

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
por: Wu, Mengling, et al.
Publicado: (2022)

Allogeneic Hematopoietic Stem Cell Transplantation in Extranodal Natural Killer/T-cell Lymphoma
por: Peng, Yin-yin, et al.
Publicado: (2021)

Prognostic value of soluble PD-L1 and exosomal PD-L1 in advanced gastric cancer patients receiving systemic chemotherapy
por: Shin, Kabsoo, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_87nvdtdbg0cd571sqd9aic8f3m